2022
DOI: 10.1016/j.asmr.2022.04.032
|View full text |Cite
|
Sign up to set email alerts
|

Reporting of Patient-Reported Outcome Measures in Randomized Controlled Trials on Shoulder Rotator Cuff Injuries Is Suboptimal and Requires Standardization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 38 publications
(60 reference statements)
1
1
0
Order By: Relevance
“…PRO-specific limitations and implications for generalizability and clinical practice were well reported in 18.97% of all RCTs of depression included in our study. This proportion was similar to that of the studies on multiple myeloma examined in another review (28) but was much lower than that of the 71 RCTs of hematological malignancies (25). More efforts should be made to improve the quality of reporting because it is helpful for clinicians and patients to assess treatment tolerability and make therapeutic decisions.…”
Section: Discussionsupporting
confidence: 63%
See 1 more Smart Citation
“…PRO-specific limitations and implications for generalizability and clinical practice were well reported in 18.97% of all RCTs of depression included in our study. This proportion was similar to that of the studies on multiple myeloma examined in another review (28) but was much lower than that of the 71 RCTs of hematological malignancies (25). More efforts should be made to improve the quality of reporting because it is helpful for clinicians and patients to assess treatment tolerability and make therapeutic decisions.…”
Section: Discussionsupporting
confidence: 63%
“…Importantly, as an integral part of PRO analysis and interpretation, handling missing data is inevitably, but about half of the articles included in this study did not state their statistical approaches for dealing with missing data completely. A systematic review assessing PRO reporting in studies on multiple myeloma found that only 23.0% reported a statistical plan for handling missing data (28). In another review of PRO reporting in randomized controlled trials of hematological malignancies, the proportion of missing data was reported in 51 (72%) of the 71 RCTs, but approaches used to handle missing data were described in only 26 (37%) trials (25).…”
Section: Discussionmentioning
confidence: 99%